Itolizumab - Phase 3 Clinical Trial
Itolizumab - Phase 3 Clinical Trial
About This Event
Phase 3 study continues to show rapid and durable complete responses, resulting in clinically meaningful reduction in corticosteroid use. 79% of responders maintained or achieved a complete response at six months, noted December 13, 2021. Pivotal study to commence early-2022. Phase 3 updated interim results to be presented at the Transplantation & Cellular Meetings of the American Society of Transplantation and Cellular Therapy, February 2-6, 2022.
Why This Event Matters
Regulatory milestones can be important for biotech and pharmaceutical names because decisions may affect timelines, labeling, and commercial prospects. Outcomes are uncertain until confirmed by the company or agency materials; this listing is informational. The date shown is February 2, 2022 (America/New_York).
Source summary: Phase 3 study continues to show rapid and durable complete responses, resulting in clinically meaningful reduction in corticosteroid use. 79% of responders maintained or achieved a complete response at six months, noted December 13, 2021. Pivotal study to commence early-2022. Phase 3 updated interim results to be presented at the Transplantation & Cellular Meetings of the American Society of...
This listing is associated with EQ. Market participants may watch these names around the event window for volatility or news flow.
Event Details
Occurs
Related Tickers
Impact Likelihood
Source
Created By
Source
Created By
Frequently Asked Questions
- What is Itolizumab - Phase 3 Clinical Trial?
- It is a stock market catalyst entry on Catacal—an event or release investors and traders may monitor. Details are summarized from the cited source and may be updated over time.
- When is Itolizumab - Phase 3 Clinical Trial?
- The calendar shows Feb 2, 2022 (America/New_York). Verify the exact time and any changes using the source link when planning around the event.
- Why does Itolizumab - Phase 3 Clinical Trial matter for investors?
- Regulatory outcomes can change timelines and risk profiles for drug and device developers.
- Which stocks or sectors could be affected?
- Symbols linked to this listing include EQ; other names in the same industry group may also move with related news.
- How is this event categorized?
- Catacal groups this entry under "FDA Approval" for navigation. Categories help you find comparable catalysts and build a week-by-week watchlist.
Track Market-Moving Events
Monitor earnings, economic releases, lockups, conferences, and other catalysts that impact stocks.
View Catalyst CalendarComprehensive Calendar
Track earnings, product launches, FDA approvals, economic events, and more.
Impact Ratings
Know which catalysts have the greatest potential to impact stock prices.
Never Miss an Event
Get alerts and reminders so you're always prepared for market-moving events.
View Catalyst Calendar
Track upcoming market events